Ignite Creation Date:
2024-05-05 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00251888
Status:
COMPLETED
Last Update Posted:
2017-01-25
First Post:
2005-11-10
Brief Title:
CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer Search of Tolerated Maximum Dose of Campto
Sponsor:
ARCAGY GINECO GROUP
Organization:
ARCAGY GINECO GROUP
Study Overview
Official Title:
Etude de Recherche de Dose de lAssociation Irinotecan CamptoR - Cisplatine CisplatylR Avec la radiothérapie Pelvienne Dans Les Cancers avancés du Col de lutérus
Status:
COMPLETED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Search of maximum tolerated irinotecan dose in association with cisplatin and pelvic radiotherapy in patients with an advanced cervix cancer
Detailed Description:
To determine the maximum and the recommended tolerated dose of irinotecan with increasing doses associated with weekly cisplatin and combinated with pelvic radiotherapy in patients with an advanced cervix cancer IIB-IVA FIGO stage
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None